The primary objective of this systematic review was to evaluate the real-world AE profile of currently-marketed CFTR modulator therapies in the treatment of people with CF, with a secondary objective of evaluating reported strategies to address or mitigate reported AEs. The gene discussed is CFTR; the disease is cystic fibrosis.